Literature DB >> 8776015

HIV-1 encephalopathy in children.

H A Gelbard1, L G Epstein.   

Abstract

HIV-1 infection is a worldwide pandemic, with an estimate of one to two million children infected by the end of the decade. The neurologic manifestations of primary HIV-1 infection in children are a major cause of morbidity and contribute to the fatal outcome in this condition. In the United States, HIV-1 is the most frequent cause of dementia in young adults. Because antiretroviral therapies and treatment for opportunistic infections have lengthened the survival time but not eradicated the virus from the central nervous system, it is likely that the incidence of neurologic dysfunction, including HIV-1 dementia, will increase. Available evidence suggests that the HIV-1 virus does not productively infect neurons but rather induces programmed cell death (apoptosis) in neurons by production of neurotoxic factors, including cytokines, phospholipid mediators, and eicosanoids, and HIV-1 gene products from HIV-1-infected macrophages in the brain. Understanding the mechanisms involved in neuronal cell injury and death may lead to new therapeutic interventions for the neurologic dysfunction associated with HIV-1 infection of the developing central nervous system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8776015     DOI: 10.1097/00008480-199512000-00005

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  16 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 2.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

3.  M-tropic HIV envelope protein gp120 exhibits a different neuropathological profile than T-tropic gp120 in rat striatum.

Authors:  Alessia Bachis; Maria I Cruz; Italo Mocchetti
Journal:  Eur J Neurosci       Date:  2010-07-28       Impact factor: 3.386

Review 4.  Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.

Authors:  R Cotter; C Williams; L Ryan; David Erichsen; A Lopez; H Peng; J Zheng
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Pharmacological induction of CCL5 in vivo prevents gp120-mediated neuronal injury.

Authors:  Lee A Campbell; Valeriya Avdoshina; Chris Day; Seung T Lim; Italo Mocchetti
Journal:  Neuropharmacology       Date:  2015-01-23       Impact factor: 5.250

Review 6.  HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Authors:  Jonathan Herskovitz; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-23       Impact factor: 4.147

Review 7.  Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: inflammation or impaired neuronal plasticity?

Authors:  V Avdoshina; A Bachis; I Mocchetti
Journal:  J Intern Med       Date:  2013-05       Impact factor: 8.989

8.  M- and T-tropic HIVs promote apoptosis in rat neurons.

Authors:  Alessia Bachis; Francesca Biggio; Eugene O Major; Italo Mocchetti
Journal:  J Neuroimmune Pharmacol       Date:  2008-11-26       Impact factor: 4.147

9.  Dose-dependent long-term effects of Tat in the rat hippocampal formation: a design-based stereological study.

Authors:  Sylvia Fitting; Rosemarie M Booze; Ulla Hasselrot; Charles F Mactutus
Journal:  Hippocampus       Date:  2010-04       Impact factor: 3.899

10.  Classification of HIV-1-mediated neuronal dendritic and synaptic damage using multiple criteria linear programming.

Authors:  Jialin Zheng; Wei Zhuang; Nian Yan; Gang Kou; Hui Peng; Clancy McNally; David Erichsen; Abby Cheloha; Shelley Herek; Chris Shi
Journal:  Neuroinformatics       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.